PAVmed Inc. (PAVM) is a New York-based medical technology company that develops and commercializes diagnostics, devices and digital health products, most visibly through its Lucid Diagnostics subsidiary, its Veris Health remote cancer-care platform, and its PortIO and Octeris device programs. Shares traded at $1.345 in Wednesday's session, down 8.16% from the prior close of $1.47, putting the stock within striking distance of its 52-week low of $1.17 and roughly 95% below its 52-week high of $28.44. The move lower is confirmed and meaningful. No fresh press release, regulatory filing or analyst revision was published before the decline; the selling is a continuation of the fade that began after the mid-November earnings report, amplified by covenant and funding concerns already on the record.
The Nov. 13 third-quarter release contained genuinely constructive operating headlines — Medicare reimbursement now flowing for Lucid's EsoGuard test, a record October test volume month, and a design freeze on Veris Health's implantable physiological monitor. The stock initially responded with conviction, climbing 21.7% to $1.63 that day and touching $2.29 intraday on Nov. 16 before closing at $1.75. That rally did not hold. Shares fell more than 16% on Nov. 17 and are down again today, leaving the price below where it stood before the earnings release. When a news-driven pop is fully retraced within three sessions, the market is typically rejecting the durability of the catalyst rather than its existence. In PAVmed's case, the parent company reported revenue of just $41,000 for the quarter and a GAAP net loss attributable to common stockholders of $11.8 million. The operational progress sits largely inside Lucid, which PAVmed no longer controls and holds only about 15% of — a distinction investors are clearly weighting heavily.
The funding structure remains the dominant bearish argument. PAVmed ended the quarter with $8.9 million in cash and equivalents, of which $5.3 million was restricted, including $5 million pledged as collateral against a $15 million senior secured note carrying a 15% interest rate. Management disclosed that the collateral coverage covenant tied to the market value of its Lucid shares was not met at Sept. 30, and the note holder has only agreed to waive the covenant through the date of the company's SEC filing. That leaves an unresolved negotiation as a live overhang. A newly established at-the-market facility of up to $9.4 million provides flexibility but also keeps dilution risk in front of shareholders, particularly with Series D warrants currently out of the money.
One of the more telling aspects of today's action is that Lucid Diagnostics (LUCD) is trading up roughly 5% near $0.42, while PAVmed is down more than 8%. Because PAVmed's equity-method investment is marked to Lucid's share price, that divergence argues against any single read-through event and points instead to PAVmed-specific positioning — sellers trimming exposure to the parent's own cash and covenant profile rather than reacting to subsidiary news.
Volume in PAVM has been running in the tens of thousands of shares, roughly in line with an average of about 22,800 shares, with recent sessions ranging from under 2,000 shares to as much as 93,000. At these levels, notional turnover is frequently below $100,000, which means relatively small orders can move the quote several percentage points. The move is not a sector event: the iShares Biotechnology ETF is down only about 0.5% and the broad S&P 500 proxy is lower by roughly 0.4%, so PAVmed's decline is many times larger than either benchmark. Technically, the stock is holding above its November low of $1.17 but remains far beneath every meaningful moving average, and the failure at the $2.29 intraday spike left a clear rejection level overhead.
A score of 0 represents no meaningful news and a normal day for the stock, while 100 represents transformative news and an extreme, rare move. PAVmed earns 22 out of 100. The verified news — an in-line third-quarter update with a non-GAAP loss that beat expectations and a Medicare reimbursement milestone at Lucid — is moderate at best relative to the parent's tiny revenue base, and it is now several sessions old. The price move is also unremarkable by this stock's standards: at 8.16%, it is about 1.6 times the average absolute daily move of roughly 5% over the past 60 sessions, and moves of equal or greater magnitude occurred 11 times in that window. Modest news plus a routine move produces a low score.
The next scheduled catalyst is fourth-quarter and full-year 2026 results, expected in late March 2027, where investors will scrutinize parent-level cash burn, the pace of ATM usage and covenant compliance. Before then, management has flagged a pending MolDX local coverage determination reconsideration for EsoGuard, an in-person FDA pre-submission meeting for PortIO in January, an initial FDA pre-submission package for Octeris, and enrollment beginning at the University of North Carolina for the Octeris clinical validation study. Veris Health's implantable monitor remains targeted for a 510(k) submission in early 2027. The principal risks are a further decline in Lucid's share price pressuring collateral coverage, continued dilution, and the possibility that Medicare reimbursement momentum at the subsidiary does not translate into value at the parent level.
Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions appear in the curated Trending AI Robots section. Each bot differs by strategy, timeframe, performance metrics and the symbols it trades, so the page functions as a live leaderboard rather than a single recommendation. For traders navigating volatile micro-caps like this one, it offers a structured way to see which systematic approaches are working right now. Explore the page to compare current leaders.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The RSI Indicator for PAVM moved out of oversold territory on November 13, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 26 of the 31 cases the stock moved higher. This puts the odds of a move higher at 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 68 cases where PAVM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for PAVM just turned positive on October 23, 2026. Looking at past instances where PAVM's MACD turned positive, the stock continued to rise in 41 of 50 cases over the following month. The odds of a continued upward trend are 82%.
Following a +33.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where PAVM advanced for three days, in 193 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
PAVM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PAVM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PAVM entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.423) is normal, around the industry mean (4.142). P/E Ratio (-0.097) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (83.333) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. PAVM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PAVM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of medical devices
Industry MedicalNursingServices